Metabolic / incretin
Retatrutide
Also known as LY3437943
39-residue triple agonist with a gGlu-C20 lipid modification
A synthetic triple agonist of the GLP-1, GIP, and glucagon receptors, studied as the next step beyond dual incretin agonists.
Retatrutide (LY3437943) is engineered to activate all three incretin/glucagon-axis receptors (GLP-1R, GIPR, GCGR). A C20 fatty-diacid attachment confers albumin binding and an extended functional half-life, and the combined receptor activity produces a distinct downstream signaling profile relative to dual or mono-agonists. It is widely used as a reference standard in comparative metabolic-receptor research.
Common research areas
- Triple-receptor activation studies
- Comparative cAMP/beta-arrestin assays vs tirzepatide & semaglutide
- In-vitro metabolic phenotype models
Watch
How Does Retatrutide Work?
Dr. Rob Swanda, PhDYouTube ↗
In our catalog
Retatrutide 20 mg · $125 CAD · ≥99% HPLC
Related compounds
Further reading
Selected references
- 1. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of RCTs. Proc (Bayl Univ Med Cent), 2025. PMID 40291085
- 2. The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity. Expert Opin Investig Drugs, 2025. PMID 40022548
- 3. What is the pipeline for future medications for obesity?. Int J Obes (Lond), 2024. PMID 38302593
For laboratory research use only. Reference information, not usage guidance or dosing advice.